MAIN STORY
An offering shaped by cautious markets
Iambic plans to sell approximately 9.38 million shares at $15 to $17 each, putting the maximum gross proceeds at roughly $159.4 million before fees and expenses. The valuation estimate of up to $805.8 million depends on the shares outstanding as described in its offering documents. Those numbers are proposed, not the final offering price or evidence that the listing has already been completed.
The company has applied to trade on the Nasdaq under the ticker IAM. J.P. Morgan, Jefferies, BofA Securities and Citigroup are leading the underwriting. Reuters reported that ARK Investment Management and Duquesne Family Office indicated interest in buying a combined $60 million of shares. Such indications can signal attention from sophisticated investors, but should not be mistaken for guaranteed completed purchases.
Why an AI-focused drugmaker attracts attention
Established in 2019 under the name Entos, the San Diego-area company uses computational models alongside laboratory experiments to design and refine drug candidates. Its approach aims to predict useful molecular structures and properties earlier in development, potentially reducing the number of unsuccessful laboratory iterations.










